Douglas Katsev is an Ophthalmology physician. OpenAlex indexes 13 publications with 257 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2946 De La Vina St
Santa Barbara, CA 931053310
Telephone
805-967-9990Provider last certified this registry record 14 Feb 2023.
Clinical trials
- Clinical Evaluation of TrueVision System: LRI and Capsulorhexis Templates
Sponsor: TrueVision Systems, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
49 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202556 payments$43,518openpaymentsdata.cms.gov ↗
- Bausch & Lomb Americas Inc.Program year202556 payments$34,204openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
55.5%Prostaglandin Analog12.9%Bimatoprost68%Latanoprost25%Lumigan7%Part D + Part B<11 patientsAminoglycoside Antibacterial9.5%Neomycin-Polymyxin-Dexameth46%Zylet33%Tobramycin-Dexamethasone12%Tobradex St9%Part D≥36 patients+ 6 more classes in this area
Anti-infectives
19.1%Tetracycline-class Drug14.4%Doxycycline Monohydrate87%Doxycycline Hyclate13%Part D≥145 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor2.8%Valacyclovir100%Part D≥22 patients+ 1 more class in this area
Dermatology
9%Corticosteroid6.1%Triamcinolone acetonide100%Part B, office-administered≥77 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3%Acyclovir100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intracameral Ketorolac Concentration After Topical Ketorolac Administration Prior to Cataract Surgery
2015 ASCRS ASOA Symposium and Congress
2015 - Two Phase 3 Trials of Bisulfite- and Preservative-Free OMS302 in Irrigation Solution for Maintenance of Mydriasis, Prevention of Miosis, and Reduction of Postoperative Pain in Intraocular Lens Replacement (ILR)2014
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”